# Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)

> **NCT00644371** · PHASE2 · COMPLETED · sponsor: **Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea** · enrollment: 20 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Ibritumomab Tiuxetan (Zevalin)

## Key facts

- **NCT ID:** NCT00644371
- **Lead sponsor:** Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2011-02-21
- **Final completion:** 2013-02-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00644371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00644371, "Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00644371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*